Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6936207 | 1.00 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL6935578 | 1.00 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL633588 | 1.00 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL6936201 | 1.00 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL6150895 | 1.00 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL633484 | 0.90 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL6866936 | 0.85 | PTGDR (0.74) | PTGDRTBXA2R | |
| SCHEMBL4648170 | 0.85 | PTGDR (0.74) | PTGDRTBXA2R | |
| SCHEMBL6866940 | 0.85 | PTGDR (0.74) | PTGDRTBXA2R | |
| SCHEMBL5176774 | 0.85 | PTGDR (0.74) | PTGDRTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772288-B2 | Substituted spiro[cycloalkyl-1,3′-indo]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2014-07-08 | — | — | US | disclosed |
| EP-2280943-B1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDO]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL SA (ES) | 2013-11-06 | — | — | EP | disclosed |
| US-8450341-B2 | Substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2013-05-28 | — | — | US | disclosed |
| US-8334294-B2 | 4,8-diphenyl-polyazanaphthalene derivatives | ALMIRALL, S.A. (ES) | 2012-12-18 | — | — | US | disclosed |
| EP-2498775-A1 | NEW 7-PHENYL-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE DERIVATIVES | Almirall S.A. (ES) | 2012-09-19 | — | — | EP | disclosed |
| US-20120225904-A1 | New 7-Phenyl-[1,2,4]triazolo[4,3-a]Pyridin-3(2H)-One Derivatives | ALMIRALL, S.A. (ES) | 2012-09-06 | — | — | US | disclosed |
| US-8258122-B2 | 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives | ALMIRALL, S.A. (ES) | 2012-09-04 | — | — | US | disclosed |
| EP-2146988-B1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | ALMIRALL SA (ES) | 2012-08-15 | — | — | EP | disclosed |
| EP-2280953-B1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL SA (ES) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011057757-A1 | NEW 7-PHENYL-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-05-19 | — | — | WO | disclosed |
| WO-2008107125-A1 | NEW 3-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES | ALMIRALL, S.A. (ES) | 2008-09-12 | — | — | WO | disclosed |
| EP-1922313-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | Laboratorios Almirall, S.A. (ES) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007017096-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
| US-20050222193-A1 | Novel combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-10-06 | — | — | US | disclosed |
| WO-2005074932-A1 | THE USE OF (S) - PANTOPRAZOLE MAGNESIUM FOR THE TREATMENT OF AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-20050165041-A1 | Combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-07-28 | — | — | US | disclosed |
| EP-1517706-A2 | COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA Pharma AG (DE) | 2005-03-30 | — | — | EP | disclosed |
| EP-1506016-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA Pharma AG (DE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003094967-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003094968-A2 | COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225904-A1 | New 7-Phenyl-[1,2,4]triazolo[4,3-a]Pyridin-3(2H)-One Derivatives | MAPK7, MAPK1, MAP3K7 | PTGDR 731/4885TBXA2R 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.